Share on StockTwits
 

Alnylam Pharmaceuticals (NASDAQ:ALNY) SVP Laurence Reid sold 20,400 shares of Alnylam Pharmaceuticals stock on the open market in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $80.06, for a total value of $1,633,224.00. Following the transaction, the senior vice president now directly owns 3,905 shares of the company’s stock, valued at approximately $312,634. The sale was disclosed in a filing with the SEC, which is available at this link.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up 7.03% on Thursday, hitting $84.70. 988,072 shares of the company’s stock traded hands. Alnylam Pharmaceuticals has a one year low of $21.60 and a one year high of $112.57. The stock has a 50-day moving average of $79.13 and a 200-day moving average of $62.6. The company’s market cap is $5.395 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Wednesday, February 19th. The company reported ($0.51) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.45) by $0.06. The company had revenue of $10.80 million for the quarter, compared to the consensus estimate of $9.98 million. During the same quarter in the prior year, the company posted ($1.20) earnings per share. The company’s quarterly revenue was up 27.1% on a year-over-year basis. Analysts expect that Alnylam Pharmaceuticals will post $-2.16 EPS for the current fiscal year.

ALNY has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Alnylam Pharmaceuticals in a research note on Monday. They now have a $83.00 price target on the stock. Separately, analysts at Needham & Company raised their price target on shares of Alnylam Pharmaceuticals from $65.00 to $84.00 in a research note on Friday, February 14th. They now have a “buy” rating on the stock. Finally, analysts at JMP Securities raised their price target on shares of Alnylam Pharmaceuticals from $68.00 to $110.00 in a research note on Friday, January 31st. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $79.50.

Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.